Brooklyn ImmunoTherapeutics Inc (NYSE:BTX - Get Free Report) rose 0.4% on Wednesday . The company traded as high as $7.32 and last traded at $7.30. Approximately 333,262 shares changed hands during mid-day trading, a decline of 55% from the average daily volume of 744,969 shares. The stock had previously closed at $7.27.
Wall Street Analyst Weigh In
Separately, Wall Street Zen initiated coverage on Brooklyn ImmunoTherapeutics in a report on Saturday, May 17th. They issued a "hold" rating for the company.
Read Our Latest Analysis on Brooklyn ImmunoTherapeutics
Brooklyn ImmunoTherapeutics Stock Performance
The stock has a fifty day simple moving average of $7.15 and a two-hundred day simple moving average of $5.43. The stock has a market capitalization of $430.61 million, a price-to-earnings ratio of -3.22 and a beta of 4.61.
Brooklyn ImmunoTherapeutics Company Profile
(
Get Free Report)
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
See Also
Before you consider Brooklyn ImmunoTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brooklyn ImmunoTherapeutics wasn't on the list.
While Brooklyn ImmunoTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
